These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

461 related articles for article (PubMed ID: 25666495)

  • 1. Novel RAAS agonists and antagonists: clinical applications and controversies.
    Romero CA; Orias M; Weir MR
    Nat Rev Endocrinol; 2015 Apr; 11(4):242-52. PubMed ID: 25666495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The evolving landscape of RAAS inhibition: from ACE inhibitors to ARBs, to DRIs and beyond.
    Epstein BJ; Leonard PT; Shah NK
    Expert Rev Cardiovasc Ther; 2012 Jun; 10(6):713-25. PubMed ID: 22894628
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of renin-angiotensin system inhibitors on mortality and major cardiovascular endpoints in hypertension: A number-needed-to-treat analysis.
    Brugts JJ; van Vark L; Akkerhuis M; Bertrand M; Fox K; Mourad JJ; Boersma E
    Int J Cardiol; 2015 Feb; 181():425-9. PubMed ID: 25569271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of ACE-inhibitors and angiotensin receptor blockers on inflammation.
    Di Raimondo D; Tuttolomondo A; Buttà C; Miceli S; Licata G; Pinto A
    Curr Pharm Des; 2012; 18(28):4385-413. PubMed ID: 22283779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of the renin angiotensin aldosterone system: focus on aliskiren.
    Rao MS
    J Assoc Physicians India; 2010 Feb; 58():102-8. PubMed ID: 20653151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reducing cardiorenal risk through combination therapy with a direct renin inhibitor.
    Rastogi A; Rashid M; Wright RF
    J Clin Hypertens (Greenwich); 2011 Nov; 13(11):848-55. PubMed ID: 22051431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Should ACE inhibitors and ARBs be used in combination in children?
    Stotter BR; Ferguson MA
    Pediatr Nephrol; 2019 Sep; 34(9):1521-1532. PubMed ID: 30112656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficiency and specificity of RAAS inhibitors in cardiovascular diseases: how to achieve better end-organ protection?
    Nehme A; Zibara K
    Hypertens Res; 2017 Nov; 40(11):903-909. PubMed ID: 28680167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renin Angiotensin Aldosterone System Inhibitors in Hypertension: Is There Evidence for Benefit Independent of Blood Pressure Reduction?
    Bavishi C; Bangalore S; Messerli FH
    Prog Cardiovasc Dis; 2016; 59(3):253-261. PubMed ID: 27777044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. It is time to reconsider the cardiovascular protection afforded by RAAS blockade -- overview of RAAS systems.
    Tsukamoto O; Kitakaze M
    Cardiovasc Drugs Ther; 2013 Apr; 27(2):133-8. PubMed ID: 22147138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current strategies to achieve further cardiac and renal protection through enhanced renin-angiotensin-aldosterone system inhibition.
    Alfie J; Aparicio LS; Waisman GD
    Rev Recent Clin Trials; 2011 May; 6(2):134-46. PubMed ID: 21241234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of Renin-Angiotensin-Aldosterone System Blockade in Patients with End-Stage Renal Disease.
    Slomka T; Lennon ES; Akbar H; Gosmanova EO; Bhattacharya SK; Oliphant CS; Khouzam RN
    Am J Med Sci; 2016 Mar; 351(3):309-16. PubMed ID: 26992264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The blockade of renin-angiotensin-aldosterone system in hemodialysis patients to control hypertension and prevent cardiovascular disease: optimal pharmacotherapy.
    Morishita Y; Kusano E
    Cardiovasc Hematol Agents Med Chem; 2011 Oct; 9(4):241-6. PubMed ID: 22023537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renal and cardio-protective effects of direct renin inhibition: a systematic literature review.
    Lambers Heerspink HJ; Perkovic V; de Zeeuw D
    J Hypertens; 2009 Dec; 27(12):2321-31. PubMed ID: 19727007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical impact of renin-angiotensin system blockade: angiotensin-converting enzyme inhibitors vs. angiotensin receptor antagonists.
    Izzo JL; Moser M
    J Clin Hypertens (Greenwich); 2002; 4(6 Suppl 2):11-9, 31. PubMed ID: 12461316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of RAAS Inhibitors in Patients with Kidney Disease.
    Zhang F; Liu H; Liu D; Liu Y; Li H; Tan X; Liu F; Peng Y; Zhang H
    Curr Hypertens Rep; 2017 Aug; 19(9):72. PubMed ID: 28791529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiorenal protection during chronic renin-angiotensin-aldosterone system suppression: evidences and caveats.
    Ruiz-Hurtado G; Ruilope LM
    Eur Heart J Cardiovasc Pharmacother; 2015 Apr; 1(2):126-31. PubMed ID: 27533982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Oral inhibitors of renin and their potential use as therapeutic agents in treating hypertension].
    Abassi Z; Armaly Z; Nakhoul F; Hoffman A
    Harefuah; 2008 Jun; 147(6):536-42, 573. PubMed ID: 18693632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of Angiotensin receptor blockers in cardiovascular disease.
    Maggioni AP
    Cardiovasc Drugs Ther; 2006 Aug; 20(4):295-308. PubMed ID: 16915347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ARBs and target organ protection. Exploring benefits beyond their antihypertensive effects.
    Silverstein RL; Fenves AZ; Ram CV
    Postgrad Med; 2004 Aug; 116(2):31-8, 41. PubMed ID: 15323152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.